Pune, India -- (SBWIRE) -- 02/24/2020 -- The Neuroendocrine Tumors market document includes historic data, present market trends, product consumption, environment, technological innovation, future prospects, upcoming technologies and the technical progress in the Healthcare industry. SWOT analysis and Porter's Five Forces Analysis are the two consistently and promisingly used tools for generating this report. Moreover, this data is also checked and verified by the market experts before publishing it into the market report and providing it to the client. Neuroendocrine Tumors market document helps businesses decide upon various strategies such as production, marketing, sales or promotion for a particular product in the market or the new product to be launched.

Global neuroendocrine tumors market is rise gradually to an estimated value of USD 2.80 Billion by 2026 registering a CAGR of 10.2% in the forecast period of 2019-2026. Increasing prevalence of neuroendocrine tumors and accelerating demand of clinical treatment and novel therapies indicates the significant growth of market.

Request for Sample Copy or PDF Here @ https://www.databridgemarketresearch.com/request-a-sample?dbmr=global-neuroendocrine-tumors-market&raksh

Few of the major competitors currently working in the global neuroendocrine tumors market are, Bristol-Myers Squibb Company, Novartis AG, Pfizer Inc., Amgen, Inc.,  Ipsen Pharma, GlaxoSmithKline Plc, Regeneron Pharmaceuticals, Mylan N.V, Sanofi S.A, Teva Pharmaceutical Industries Ltd, F. Hoffmann-La Roche Ltd, Merck & Co., Inc., Eli Lilly and Company, AbbVie Inc., Advanced Accelerator Applications and among others

Market Definition: Global Neuroendocrine Tumors Market:-

Neuroendocrine tumors are an oncology disorder in which cancer arises from neuroendocrine cells and proliferate almost all over the body. The organs affected by neuroendocrine tumors are mainly, gastrointestinal (GI) tract, gallbladder, pancreas, lungs and thyroid. It is seen rarely in thymus, kidneys, liver, prostate, skin and ovaries. The patient may experience indigestion, abdominal pain, difficulty in breathing, muscle weakness, jaundice, weight loss etc.

According to the statistics published in American Society of Clinical Oncology, the total prevalent population of neuroendocrine tumors in United States was over 170,000, it is estimated that 12,000 new cases of patients in United States diagnosed with neuroendocrine tumors each year.

Browse Detailed TOC Here @ https://www.databridgemarketresearch.com/toc?dbmr=global-neuroendocrine-tumors-market&raksh

Segmentation: Global Neuroendocrine Tumors Market:-

Neuroendocrine Tumors Market : By Site of Origin

Carcinoid tumors in the lungs
Pancreatic neuroendocrine tumors
Medullary thyroid carcinoma
Merkel cell carcinoma
Pheochromocytoma of the adrenal gland
Small cell lung cancer
Large cell lung cancer
Others

Neuroendocrine Tumors Market : By Therapy Type

Chemotherapy
Hormonal therapy
Immunotherapy
Surgery
Medication
Others

Neuroendocrine Tumors Market : By Mechanism of Cation type

Somatostatin analogs
Tyrosine kinase inhibitor
Peptide receptor radionuclide
Alfa-interferon
Proton-pump inhibitors
Others

Neuroendocrine Tumors Market : By Drug Type

Everolimus
Sunitinib malate
Lorlatinib
Nivolumab
Dacomitinib
Brigatinib
Durvalumab
Atezolizumab
Alectinib
Crizotinib
Topotecan hydrochloride
Bevacizumab
Others

Neuroendocrine Tumors Market : By Route of administration

Oral
Intravenous
Others

Neuroendocrine Tumors Market : By End Users

Hospitals
Homecare
Specialty Clinics
Others

Neuroendocrine Tumors Market : By Geography

North America
South America
Europe
Asia-Pacific
Middle East & Africa

Key Developments in the Market:-

In January 2018, Advanced Accelerator Applications received FDA approval for Lutathera (lutetium Lu 177 dotatate), a radioactive somatostatin receptor acting as a Peptide Receptor Radionuclide Therapy (PRRT), indicated for the treatment of adult patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Previously, drug also received Orphan Drug designation by both the US FDA and European Medicines Agency (EMA)

In April 2019, Merck & Co., Inc received expanded approval from the US FDA for Keytruda (pembrolizumab), an anti-PD-1 therapy as a first line treatment of patients with stage III non-small cell lung cancer

Neuroendocrine Tumors Market Drivers:-

Increase in prevalence rate of neuroendocrine tumor in geriatric population worldwide
Accelerating demand of treatment and novel therapies
Rising awareness about treatment and technological advancement is driving the growth of market

Neuroendocrine Tumors Market Restraints:-

Effective treatment is either unavailable or unaffordable

Patent expiry from many companies and introduction of generic drugs is expected to restrain the growth if the market

Lack of awareness about novel therapies and clinical development for neuroendocrine tumors

Competitive Analysis: Global Neuroendocrine Tumors Market:-

Global neuroendocrine tumors market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of neuroendocrine tumors market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa

Neuroendocrine Tumors Market : Primary Respondents:-

Demand Side: Doctors, Surgeons, Medical Consultants, Nurses, Hospital Buyers, Group Purchasing Organizations, Associations, Insurers, Medical Payers, Healthcare Authorities, Universities, Technological Writers, Scientists, Promoters, and Investors among others.

Supply Side: Product Managers, Marketing Managers, C-Level Executives, Distributors, Market Intelligence, and Regulatory Affairs Managers among others.

Reasons to Purchase this Report:-

Current and future of global neuroendocrine tumors market outlook in the developed and emerging markets

The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period

Regions/Countries that are expected to witness the fastest growth rates during the forecast period

The latest developments, market shares, and strategies that are employed by the major market players

Customization of the Report:-

All segmentation provided above in this report is represented at country level

All products covered in the market, product volume and average selling prices will be included as customizable options which may incur no or minimal additional cost (depends on customization)

Want Full Report? Enquire Here @ https://www.databridgemarketresearch.com/inquire-before-buying?dbmr=global-neuroendocrine-tumors-market&raksh

About Data Bridge Market Research
Data Bridge Market Research is a versatile market research and consulting firm with over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Our coverage of industries include Medical Devices, Pharmaceuticals, Biotechnology, Semiconductors, Machinery, Information and Communication Technology, Automobiles and Automotive, Chemical and Material, Packaging, Food and Beverages, Cosmetics, Specialty Chemicals, Fast Moving Consumer Goods, Robotics, among many others.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude.We are content with our glorious 99.9 % client satisfying rate.

Contact Us:-

Data Bridge Market Research
US: +1 888 387 2818
UK: +44 208 089 1725
Hong Kong: +852 8192 7475
Mail: Corporatesales@databridgemarketresearch.com